drugset / Trial / NCT00660998

Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes

NCT00660998

Phase 4 Completed 318 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

Asses efficacy of Vardenafil in patients with type 1 diabetes and erectile dysfunction

Timeline

Start
2003-02
Primary completion
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vardenafil Small molecule 5 mg
Subject Vardenafil Small molecule 10 mg
Subject Vardenafil Small molecule 20 mg

Indications